Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Neuropharmacology. 2014 Jan 24;79:668–678. doi: 10.1016/j.neuropharm.2014.01.023

Figure 3. In vitro uptake and degradation of 125I-Aβ40 by bEnd3 and hCMEC/D3 cells.

Figure 3

A) In vitro uptake of intact 125I-Aβ40 by bEnd3 and hCMEC/D3 cells. Cellular level of intact 125I-Aβ40 is expressed in fmole/mg protein following cells treatment with 0.1 nM 125I-Aβ40 without (control; CNTRL) and with RAGE (RAGE-IgG), or P-gp (valspodar; VALSP), or LRP1 (RAP) inhibitors for 15 min and 12 h in bEnd3 and hCMEC/D3, respectively. B) Percent of degraded 125I-Aβ40 in the media of bEnd3 and hCMEC/D3 cells following treatment with 0.1 nM of 125I-Aβ40, with or without inhibitor. Data represent mean±SEM from three independent experiments; *P<0.05, **P< 0.01 and *** P<0.001.